Sanofi
SNY
$52.76
$0.440.84%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | 40.00B | 39.29B | 40.55B | |
| Total Other Revenue | -- | 3.61B | 3.61B | 3.43B | |
| Total Revenue | -- | 43.61B | 42.89B | 43.98B | |
| Cost of Revenue | -- | 13.55B | 13.45B | 13.53B | |
| Gross Profit | -- | 30.06B | 29.44B | 30.45B | |
| SG&A Expenses | -- | 9.24B | 9.19B | 9.70B | |
| Depreciation & Amortization | -- | 1.99B | 2.05B | 2.05B | |
| Other Operating Expenses | -- | 4.67B | 4.17B | 4.04B | |
| Total Operating Expenses | -- | 36.64B | 35.99B | 36.30B | |
| Operating Income | -- | 6.97B | 6.91B | 7.68B | |
| Income Before Tax | -- | 4.74B | 5.08B | 6.54B | |
| Income Tax Expenses | -- | 735.06M | 708.22M | 1.09B | |
| Earnings from Continuing Operations | -- | 4.00K | 4.38K | 5.46K | |
| Earnings from Discontinued Operations | -- | 170.44M | 170.44M | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -28.88M | -37.63M | -38.53M | |
| Net Income | -- | 4.51B | 4.87B | 5.78B | |
| EBIT | -- | 6.97B | 6.91B | 7.68B | |
| EBITDA | -- | 10.26B | 10.24B | 11.02B | |
| EPS Basic | -- | 3.60 | 3.89 | 4.62 | |
| Normalized Basic EPS | -- | 0.80 | 0.78 | 0.78 | |
| EPS Diluted | -- | 3.59 | 3.89 | 4.61 | |
| Normalized Diluted EPS | -- | 0.79 | 0.78 | 0.78 | |
| Average Basic Shares Outstanding | -- | 5.00B | 5.00B | 5.00B | |
| Average Diluted Shares Outstanding | -- | 5.02B | 5.01B | 5.01B | |
| Dividend Per Share | -- | 4.05 | 4.05 | 4.05 | |
| Payout Ratio | -- | -- | -- | -- | |